PI16 attenuates response to sorafenib and represents a predictive biomarker in hepatocellular carcinoma
Abstract Sorafenib has become the only FDA‐approved first‐line therapy for advanced hepatocellular carcinoma (HCC) for more than 10 years, but there is still no validated predictive or prognostic marker. Peptidase inhibitor 16 (PI16) is a functionally unknown gene in cancer research. This study aime...
Main Authors: | Pusen Wang, Zhongyi Jiang, Xueni Liu, Kanru Yu, Chunguang Wang, Hao Li, Lin Zhong |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2020-10-01
|
Series: | Cancer Medicine |
Subjects: | |
Online Access: | https://doi.org/10.1002/cam4.3331 |
Similar Items
-
Ellagic acid inhibits tumor growth and potentiates the therapeutic efficacy of sorafenib in hepatocellular carcinoma
by: Zhenju Tan, et al.
Published: (2024-01-01) -
Metformin Enhances the Anti-Cancer Efficacy of Sorafenib via Suppressing MAPK/ERK/Stat3 Axis in Hepatocellular Carcinoma
by: Sumit Siddharth, et al.
Published: (2022-07-01) -
Liver-Directed Concurrent Chemoradiotherapy versus Sorafenib in Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis
by: Jina Kim, et al.
Published: (2022-05-01) -
Augmented Efficacy of Uttroside B over Sorafenib in a Murine Model of Human Hepatocellular Carcinoma
by: Mundanattu Swetha, et al.
Published: (2022-05-01) -
Combining Crocin and Sorafenib Improves Their Tumor-Inhibiting Effects in a Rat Model of Diethylnitrosamine-Induced Cirrhotic-Hepatocellular Carcinoma
by: Basma Awad, et al.
Published: (2023-08-01)